地尔硫卓联合地高辛治疗心力衰竭并慢性快速房颤分析

目的观察地尔硫卓联合小剂量地高辛对心力衰竭并慢性快速房颤患者血压、心室率和心功能的影响。方法 :心功能Ⅱ～Ⅲ级慢性房颤患者 10 6例 ,随机分为二组 ,对照组 5 0例 ,单用地高辛 ,治疗组 5 6例 ,地尔硫卓与地高辛联用 ,其余治疗二组相同 ,7～ 10d为一疗程 ,观察治疗前后血压、心率、左室射血分数 (LVEF)、心输出量 (CO)。结果 :治疗组较对照组心室率明显下降 ,控制满意 ,血压、LVEF及CO变化二组相似。结论 :地尔硫卓联合小剂量地高辛治疗心衰并慢性快速房颤患者心室率较单用地高辛效果更好 ,且较为安全。     

地高辛和卡托普利相互作用的监测

本文选择20例充血性心力衰竭患者。联合应用地高辛和卡托普利治疗,观察两药的相互作用。先口服地高辛0.25mg,1次/d,达稳态血浓度后,加服卡托普利12.5mg～25mg,3次/d。监测加服卡托普利前后的血清地高辛浓度。两者问无显著性差异,提示卡托普利对血清地高辛浓度影响不大,无明显相互作用。     

刺五加对豚鼠地高辛中毒的影响

豚鼠灌服地高辛复制地高辛中毒模型，研究五加对地高辛中毒的影响。结果发现，服刺五加组豚鼠发生心律失常较未给药组明显推迟，而血中地高辛浓度则显著高于未给药组，提未临床应用地高辛时同时给予刺五加有于减少减轻地高辛的毒性反应。     

地高辛、维生素B1混合粉末在常温下的稳定性考察

目的：研究地高辛与维生素B1混合粉末在常温下的稳定性。方法：在25℃条件下，采用紫外分光光度法，测定其含量、重量在10、20、30、40、50天的变化情况。结果：在25℃下，混合粉末在30天前基本稳定。结论：地高辛、维生素B1混合粉末保存不应大于30天。     

地高辛标记DNA探针快速筛选肿瘤细胞株基因表达差异

目的建立寡核苷酸探针正向斑点杂交技术,快速筛选不同细胞株同一基因HIF-1a表达差异,探讨斑点杂交筛选基因表达的可行性。方法将多种培养肿瘤细胞株提取总RNA后,点样于尼龙膜上,与地高辛标记的HIF-1a基因探针杂交,结果与半定量RT-PCR结果比较。结果斑点杂交实验结果与RT-PCR结果一致,无统计学差异(P>0.05)。结论用随机引物地高辛标记DNA探针可以快速筛查不同细胞株同一基因表达差异,可以作为研究肿瘤基因表达差异的工具。     

严重充血性心力衰竭患者自主神经功能与心率变异的关系及地高辛的影响

对２５例重度充血性心力衰竭（ＣＨＦ）患者在地高辛治疗前后测定血浆去甲肾上腺素（ＮＥ）及心率变异（ＨＲＶ）。结果显示：ＮＥ基础值与ＨＲＶ时域指标基础水平均呈负相关（Ｐ＜０．０５或＜０．０１）。地高辛治疗前后的ＮＥ相比（２９１±８０ｐｇ／ｍｌｖｓ２１３±８２ｐｇ／ｍｌ），Ｐ＜０．００１。２４小时平均ＲＲ间期及２４小时正常ＲＲ间期标准差由治疗前的７２７±１２３ｍｓ及６７．７±２１．８ｍｓ分别增加至７７７±１２２ｍｓ及８７．２±２９．２ｍｓ（Ｐ均＜０．０５）；２４小时相邻ＲＲ间期差值的均方根（ＲＭＳＳＤ）、２４小时正常相邻ＲＲ间期之差大于５０ｍｓ的心搏数所占百分比（ＰＮＮ５０）及高频（ＨＦ）由治疗前的３６．３±３０．６ｍｓ、５．３±５．５％及３７．１±２１．２ｍｓ２分别增加至５６．１±４３．７ｍｓ、１０．８±１０．６％及７９．９±５８．２ｍｓ２（Ｐ值＜０．０５至＜０．０１）；低频（ＬＦ）由治疗前的１１８．９±１３３．２ｍｓ２增加至１７１．２±１７２．８ｍｓ２（Ｐ＜０．００５）；ＮＥ下降幅度与时域指标增加幅度均呈正相关。ＨＲＶ多数时域指标增加幅度及其绝对值与血清地高辛浓度呈正相关，以ＲＭＳＳＤ和ＰＮＮ５０尤为显著（Ｐ?     

地高辛联合倍他乐克治疗心力衰竭并发心房纤颤的疗效观察

目的观察地高辛联合倍他乐克治疗慢性心力衰竭合并心房纤颤的效果。方法选择慢性心力衰竭合并快速心房纤颤患者70例,随机分成2组。治疗组35例采用地高辛+倍他乐克治疗;对照组35例,采用地高辛治疗。12周后观察心室率和左心室射血分数(LVEF)变化的情况。结果地高辛+倍他乐克治疗组改善心室率和LVEF的疗效明显强于地高辛,差异有统计学意义(P0.01)。结论地高辛与倍他乐克联用治疗慢性心力心房纤颤伴快速心房纤颤取得了较好的疗效。     

生脉注射液对心力衰竭患者地戈辛血药浓度和药动学参数影响的临床研究

[目的]探讨生脉注射液对心力衰竭患者地戈辛血药浓度和药动学参数的影响。[方法]选择符合标准的充血性心衰患者40例 ,随机分为地戈辛组和地戈辛 +生脉注射液20、40、60mL3个剂量组 ,每组10例 ,采用放免法(RIA)分别测定4组患者不同时间地戈辛血药浓度 ,以3P97药动学软件拟合地戈辛药动学参数。[结果]生脉注射液小剂量 (20mL)组对心衰患者地戈辛血药浓度和消除半衰期 (T1/2)、表观分布容积 (Vd)、血浆清除率 (CL)等药动学参数有显著影响 (P<0.05) ,而中剂量(40mL)和大剂量 (60mL)组无明显影响(P>0.05)。[结论]提示生脉注射液在小剂量应用时具有降低充血性心衰患者地戈辛血药浓度、缩短消除半衰期的作用。     

Effect of digoxin in patients with heart failure and mid‐range (borderline) left ventricular ejection fraction

Aims

To evaluate the effects of digoxin in patients with the newly described phenotype of heart failure (HF) and mid‐range ejection fraction (HFmrEF), attributed to mild left ventricular systolic dysfunction.

Methods and results

We carried out a retrospective analysis of the Digitalis Investigation Group (DIG) trial which had 7788 patients available for analysis with a left ventricular ejection fraction (LVEF) ranging between 3% and 85%. We compared the effect of digoxin to placebo in three mutually exclusive groups of patients defined by LVEF category: <40% (HF with reduced LVEF, HFrEF, n = 5874), 40–49% (HFmrEF, n = 1195) and ≥50% (HF with preserved LVEF, HFpEF, n = 719). The primary outcome was the composite of cardiovascular death or HF hospitalisation. Patients with HFmrEF resembled patients with HFrEF, more than those with HFpEF, with respect to age, sex and aetiology but were more like HFpEF patients with respect to blood pressure and the prevalence of hypertension. Event rates in patients with HFmrEF were similar to those in HFpEF and much lower than in HFrEF. Digoxin reduced the primary endpoint in patients with HFrEF, mainly due to reduced HF hospitalisation: the digoxin/placebo hazard ratio (HR) for HF hospitalisation was 0.71 [95% confidence interval (CI) 0.65–0.77]. The digoxin/placebo HR for HF hospitalisation in patients with HFmrEF was 0.80 (95% CI 0.63–1.03) and 0.85 (95% CI 0.62–1.17) in those with HFpEF. The digoxin/placebo HR for the composite of HF death or HF hospitalisation was 0.74 (95% CI 0.68–0.81) in HFrEF, 0.83 (95% CI 0.66–1.05) in HFmrEF and 0.88 (95% CI 0.65–1.19) in HFpEF.

Conclusions

In this study, event rates in patients with HFmrEF were closer to those in HFpEF than HFrEF. Digoxin had most effect on HF hospitalisation in patients with HFrEF, an intermediate effect in HFmrEF, and the smallest effect in HFpEF.